Cover Image
市場調查報告書

PharmaPoint:躁鬱症 - 全球醫藥品市場預測與市場分析

PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 358522
出版日期 內容資訊 英文 440 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:躁鬱症 - 全球醫藥品市場預測與市場分析 PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
出版日期: 2016年03月01日 內容資訊: 英文 440 Pages
簡介

躁鬱症,是有躁症和鬱症兩極性特徵的精神疾病。

本報告提供躁鬱症治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 分類
  • 症狀
  • 預後

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 流行病學預測
    • 12個月的患者數
    • 12個月的患者數:各年齡
    • 12個月的患者數:性別
    • 12個月的患者數:年齡調整等
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷概要
  • 治療概要
  • 治療的指南主要的處方藥
  • 美國
  • EU5個國家
  • 日本
  • 加拿大

第6章 競爭評估

  • 概要
  • 產品簡介:領導品牌
  • 其他藥效分類

第7章 未滿足需求和機會

第8章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 初期開發中的有潛力的藥劑
  • 其他開發中的藥物

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • 大塚製藥
    • AstraZeneca
    • Eli Lilly
    • Allergan
    • 大日本住友製藥
    • Janssen
    • Lundbeck
    • Meiji Seika Pharma

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本
  • 加拿大

第11章 附錄

圖表

目錄
Product Code: GDHC124PIDR

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka's Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

Highlights

Key Questions Answered

  • The bipolar disorder market is heavily genericized and many key players have chosen to deprioritize the indication. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
  • The current late-stage bipolar disorder pipeline is sparse, with only two products in Phase III development. What impact will these drugs have on the market? How will they affect the treatment algorithm for bipolar disorder? Will these drugs fulfil any of the unmet needs for bipolar disorder?
  • The management of bipolar disorder patients is challenging and a large number of variables can impact treatment outcomes. How does the diagnosis and treatment of bipolar disorder differ amongst the 8MM? Which treatment options are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

Key Findings

  • The main driver of growth in the bipolar disorder market will be the uptake of novel atypical antipsychotic products, such as Otsuka/Lundbeck's Abilify Maintena and Allergan/Gedeon Richter/Mitsubishi Tanabe's Vraylar. These agents are forecast to be the highest selling bipolar disorder products by 2024, accounting for 34.9% of the bipolar disorder market in the 8MM.
  • There are very few products approved for the treatment of major depressive episodes, despite the fact that patients most commonly experience this episode type. This unmet need is not expected to be addressed during the forecast period due to the sparsity of the late-stage pipeline.
  • The biggest barrier for growth in the bipolar disorder market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.
  • Considerable opportunity remains for products with superior safety profiles compared to the currently available drugs. KOLs noted that EPS and metabolic changes were significant concerns related to the antipsychotic drugs.

Scope

  • Overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized bipolar disorder market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the bipolar disorder therapeutics market.
  • Pipeline analysis: focus on two late-stage pipeline bipolar disorder drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of off-label treatments.
  • Analysis of the current and future market competition in the global bipolar disorder therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global bipolar disorder therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bipolar disorder therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global bipolar disorder therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of Bipolar Disorder (2014-2024)
    • 4.5.1. 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder
    • 4.5.2. 12-Month Total Prevalent Cases of Bipolar I
    • 4.5.3. 12-Month Total Prevalent Cases of Bipolar II
    • 4.5.4. 12-Month Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.5. Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder
    • 4.5.6. Age-Specific 12-Month Total Prevalent Cases of Bipolar I
    • 4.5.7. Age-Specific 12-Month Total Prevalent Cases of Bipolar II
    • 4.5.8. Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.9. Sex-Specific 12-Month Total Prevalent Cases of Bipolar I
    • 4.5.10. Sex-Specific 12-Month Total Prevalent Cases of Bipolar II
    • 4.5.11. Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
    • 4.5.12. Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis Overview
    • 5.1.1. Clinical Evaluation
    • 5.1.2. Screening Tools
  • 5.2. Treatment Overview
    • 5.2.1. Treatment Initiation and Maintenance Therapy
    • 5.2.2. Manic or Mixed Episodes
    • 5.2.3. Acute Agitation
    • 5.2.4. Hypomanic Episodes
    • 5.2.5. Major Depressive Episodes
    • 5.2.6. Rapid Cycling
    • 5.2.7. Cyclothymia
    • 5.2.8. Other Treatment Factors
  • 5.3. Treatment Guidelines and Leading Prescribed Drugs
  • 5.4. US
  • 5.5. 5EU
  • 5.6. Japan
  • 5.7. Canada

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Lithium
    • 6.2.2. Anticonvulsants
    • 6.2.3. Typical Antipsychotics
    • 6.2.4. Atypical Antipsychotics
    • 6.2.5. Antidepressants
  • 6.3. Other Therapeutic Classes

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Effective Treatment Options for Bipolar Depression
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Antipsychotics with a Low Risk of EPS and Metabolic Changes
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Mood Stabilizers with Improved Safety Profiles
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Education for Physicians in Order to Improve Diagnosis Rates
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Novel Drugs Developed Specifically for Bipolar Disorder
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
    • 8.1.1. Clinical Trials by Class of Therapy
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Abilify Maintena
    • 8.2.2. ITI-007
  • 8.3. Off-label Pipeline and Recently Approved Therapies
  • 8.4. Promising Drugs in Early-Stage Development
  • 8.5. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Otsuka
    • 9.3.2. AstraZeneca
    • 9.3.3. Eli Lilly
    • 9.3.4. Allergan
    • 9.3.5. Dainippon Sumitomo
    • 9.3.6. Janssen
    • 9.3.7. Lundbeck
    • 9.3.8. Meiji Seika

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Canada
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Bipolar Disorder Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Generic Erosion
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Director of Therapy Research and Analysis
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM
  • Table 2: DSM-V Bipolar Disorder Specifiers
  • Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder
  • Table 4: Risk Factors and Comorbidities for Bipolar Disorder
  • Table 5: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder I
  • Table 6: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder I
  • Table 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder II
  • Table 8: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder II
  • Table 9: 8MM, Sources Used to Forecast 12-Month Total Prevalent Cases of Cyclothymic Disorder
  • Table 10: 8MM, Sources Used to Forecast Lifetime Total Prevalent Cases of Cyclothymic Disorder
  • Table 11: 8MM, 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages ≥13 Years, N (Row %), 2014
  • Table 12: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, 2014-2024
  • Table 13: 8MM, 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages ≥13 Years, 2014-2024
  • Table 14: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, 2014-2024
  • Table 15: 8MM, Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages ≥13 Years, N (Row %), 2014
  • Table 16: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, N (Row %), 2014
  • Table 17: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages ≥13 Years, N (Row %), 2014
  • Table 18: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, N (Row %), 2014
  • Table 19: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages ≥13 Years, N (Row %), 2014
  • Table 20: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages ≥13 Years, N (Row %), 2014
  • Table 21: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages ≥13 Years, N (Row %), 2014
  • Table 22: Screening Tools Used for Bipolar Disorder
  • Table 23: Treatment Guidelines for Bipolar Disorder
  • Table 24: Most Prescribed Drugs for Bipolar Disorder by Episode Type in the Global Markets, 2014
  • Table 25: Country Profile - US
  • Table 26: Country Profile - 5EU
  • Table 27: Country Profile - Japan
  • Table 28: Country Profile - Canada
  • Table 29: Leading Treatments for Bipolar Disorder, 2015
  • Table 30: Product Profile - Lithium
  • Table 31: Lithium SWOT Analysis, 2015
  • Table 32: Global Sales Forecasts ($m) for Lithium, 2014-2024
  • Table 33: Product Profile - Carbamazepine
  • Table 34: Efficacy Results for Equetro in Bipolar Mania Trials
  • Table 35: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Equetro
  • Table 36: Carbamazepine SWOT Analysis, 2015
  • Table 37: Global Sales Forecasts ($m) for Carbamazepine, 2014-2024
  • Table 38: Product Profile - Lamotrigine
  • Table 39: Adverse Events at ≥5% Incidence in Bipolar Maintenance Trials of Lamictal
  • Table 40: Lamotrigine SWOT Analysis, 2015
  • Table 41: Global Sales Forecasts ($m) for Lamotrigine, 2014-2024
  • Table 42: Product Profile - Valproate
  • Table 43: Efficacy Results for Depakote in Bipolar Mania Trials
  • Table 44: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Depakote
  • Table 45: Valproate SWOT Analysis, 2015
  • Table 46: Global Sales Forecasts ($m) for Valproate, 2014-2024
  • Table 47: Typical Antipsychotics by Chemical Class
  • Table 48: Typical antipsychotics SWOT Analysis, 2015
  • Table 49: Global Sales Forecasts ($m) for the Typical Antipsychotics, 2014-2024
  • Table 50: Product Profile - Adasuve
  • Table 51: Efficacy Results for Adasuve in Agitation Trial of Bipolar I Disorder Patients
  • Table 52: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve
  • Table 53: Adasuve SWOT Analysis, 2015
  • Table 54: Global Sales Forecasts ($m) for Adasuve, 2014-2024
  • Table 55: Product Profile - Abilify
  • Table 56: Efficacy Results for Abilify in Bipolar Mania Trials
  • Table 57: Efficacy Results for Abilify in Agitation Trials
  • Table 58: Adverse Events at ≥2% Incidence in Bipolar I Disorder and Schizophrenia Trials of Abilify
  • Table 59: Abilify SWOT Analysis, 2015
  • Table 60: Global Sales Forecasts ($m) for Abilify, 2014-2024
  • Table 61: Product Profile - Geodon
  • Table 62: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Geodon
  • Table 63: Geodon SWOT Analysis, 2015
  • Table 64: Global Sales Forecasts ($m) for Geodon, 2014-2024
  • Table 65: Product Profile - Latuda
  • Table 66: Efficacy Results for Latuda in Bipolar Depression Trials
  • Table 67: Adverse Events at ≥2% Incidence in Bipolar Depression Trials of Latuda
  • Table 68: Latuda SWOT Analysis, 2015
  • Table 69: Global Sales Forecasts ($m) for Latuda, 2014-2024
  • Table 70: Product Profile - Risperdal
  • Table 71: Efficacy Results for Risperdal in Trial of Manic and Mixed Bipolar Episodes
  • Table 72: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Risperdal
  • Table 73: Adverse Events at ≥2% Incidence in Bipolar Maintenance Trials of Risperdal Consta
  • Table 74: Risperdal SWOT Analysis, 2015
  • Table 75: Global Sales Forecasts ($m) for Risperdal, 2014-2024
  • Table 76: Global Sales Forecasts ($m) for Risperdal Consta, 2014-2024
  • Table 77: Product Profile - Saphris
  • Table 78: Efficacy Results for Saphris in Bipolar Mania Studies
  • Table 79: Adverse Events at ≥2% Incidence in Bipolar I Disorder Trials of Saphris
  • Table 80: Saphris SWOT Analysis, 2015
  • Table 81: Global Sales Forecasts ($m) for Saphris, 2014-2024
  • Table 82: Product Profile - Seroquel
  • Table 83: Efficacy Results for Seroquel in Bipolar Mania Studies
  • Table 84: Efficacy Results for Seroquel in Bipolar Depression Trials
  • Table 85: Efficacy Results for Seroquel XR in Bipolar Disorder Trials
  • Table 86: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel
  • Table 87: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel XR
  • Table 88: Seroquel SWOT Analysis, 2015
  • Table 89: Global Sales Forecasts ($m) for Seroquel, 2014-2024
  • Table 90: Global Sales Forecasts ($m) for Seroquel XR, 2014-2024
  • Table 91: Product Profile - Symbyax
  • Table 92: Efficacy Results for Symbyax in Bipolar Depression Trials
  • Table 93: Adverse Events at ≥2% Incidence in Bipolar Depression and Treatment-Resistant Depression Trials of Symbyax
  • Table 94: Symbyax SWOT Analysis, 2015
  • Table 95: Global Sales Forecasts ($m) for Symbyax, 2014-2024
  • Table 96: Product Profile - Vraylar
  • Table 97: Vraylar SWOT Analysis, 2015
  • Table 98: Global Sales Forecast ($) for Vraylar, 2014-2024
  • Table 99: Product Profile - Zyprexa
  • Table 100: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Zyprexa
  • Table 101: Adverse Events at ≥2% Incidence in Trials of Zyprexa IntraMuscular in Agitation Associated with Schizophrenia or Bipolar I Mania
  • Table 102: Zyprexa SWOT Analysis, 2015
  • Table 103: Global Sales Forecasts ($m) for Zyprexa, 2014-2024
  • Table 104: Product Information for the Most Commonly Prescribed "Other Antipsychotics"
  • Table 105: International Society for Bipolar Disorders Clinical Recommendations for Antidepressant Use in Bipolar Disorder
  • Table 106: Antidepressants SWOT Analysis, 2015
  • Table 107: Global Sales Forecasts ($m) for the Antidepressants, 2014-2024
  • Table 108: Summary of Minor Therapeutic Classes, 2015
  • Table 109: Unmet Need and Opportunity in Bipolar Disorder
  • Table 110: Product Profile - Abilify Maintena
  • Table 111: Adverse Events at ≥2% Incidence in a Schizophrenia Trial of Abilify Maintena
  • Table 112: Abilify Maintena SWOT Analysis, 2015
  • Table 113: Global Sales Forecast ($) for Abilify Maintena, 2014-2024
  • Table 114: Product Profile - ITI-007
  • Table 115: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial
  • Table 116: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007
  • Table 117: ITI-007 SWOT Analysis, 2015
  • Table 118: Potential Off-label Bipolar Disorder Late-Stage Pipeline Drugs
  • Table 119: Drugs in Development, 2015
  • Table 120: Key Companies in the Bipolar Disorder Market in the 8MM, 2015
  • Table 121: Otsuka's Bipolar Disorder Portfolio Assessment, 2015
  • Table 122: AstraZeneca's Bipolar Disorder Portfolio Assessment, 2015
  • Table 123: Eli Lilly's Bipolar Disorder Portfolio Assessment, 2015
  • Table 124: Allergan's Bipolar Disorder Portfolio Assessment, 2015
  • Table 125: Dainippon Sumitomo's Bipolar Disorder Portfolio Assessment, 2015
  • Table 126: Janssen Bipolar Disorder Portfolio Assessment, 2015
  • Table 127: Lundbeck Bipolar Disorder Portfolio Assessment, 2015
  • Table 128: Meiji Seika Bipolar Disorder Portfolio Assessment, 2015
  • Table 129: Global Sales Forecast ($m) for Bipolar Disorder, 2014-2024
  • Table 130: Bipolar Disorder Market - Drivers and Barriers, 2014-2024
  • Table 131: Sales Forecast ($m) for Bipolar Disorder in the US, 2014-2024
  • Table 132: Key Events Impacting Sales for Bipolar Disorder in the US, 2014-2024
  • Table 133: Bipolar Disorder Market in the US - Drivers and Barriers, 2014-2024
  • Table 134: Sales Forecasts ($m) for Bipolar Disorder in the 5EU, 2014-2024
  • Table 135: Key Events Impacting Sales for Bipolar Disorder in the 5EU, 2014-2024
  • Table 136: Bipolar Disorder Market in the 5EU - Drivers and Barriers, 2014-2024
  • Table 137: Sales Forecasts ($m) for Bipolar Disorder in Japan, 2014-2024
  • Table 138: Key Events Impacting Sales for Bipolar Disorder in Japan, 2014-2024
  • Table 139: Bipolar Disorder Market in Japan - Drivers and Barriers, 2014-2024
  • Table 140: Sales Forecasts ($m) for Bipolar Disorder in Canada, 2014-2024
  • Table 141: Key Events Impacting Sales for Bipolar Disorder in Canada, 2014-2024
  • Table 142: Bipolar Disorder Market in Canada - Drivers and Barriers, 2014-2024
  • Table 143: Key Launch Dates
  • Table 144: Key Patent Expiries
  • Table 145: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: The Etiology and Pathophysiology of Bipolar Disorders
  • Figure 2: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, 2014-2024
  • Figure 3: 8MM, Bipolar II 12-Month Total Prevalent Cases, Both Sexes, Ages ≥13 Years, 2014-2024
  • Figure 4: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, 2014-2024
  • Figure 5: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, 2014
  • Figure 6: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, 2014
  • Figure 7: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, 2014
  • Figure 8: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages ≥13 Years, 2014
  • Figure 9: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages ≥13 Years, 2014
  • Figure 10: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages ≥13 Years, 2014
  • Figure 11: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Men, Ages ≥13 Years, 2014
  • Figure 12: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Women, Ages ≥13 Years, 2014
  • Figure 13: The Effects of Lithium on Neurotransmission
  • Figure 14: The Effects of Lithium on Second Messenger Pathways
  • Figure 15: Bipolar Disorder Therapeutics - Class of Therapy, 2016
  • Figure 16: Bipolar Disorder - Phase II-III Pipeline, 2015
  • Figure 17: Clinical and Commercial Positioning of Abilify Maintena
  • Figure 18: Clinical and Commercial Positioning of ITI-007
  • Figure 19: Global Sales of Products for Bipolar Disorder by Company, 2014-2024
  • Figure 20: Company Portfolio Gap Analysis in Bipolar Disorder, 2014-2024
  • Figure 21: Otsuka SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 22: AstraZeneca SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 23: Eli Lilly SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 24: Allergan SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 25: Dainippon Sumitomo SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 26: Janssen SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 27: Lundbeck SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 28: Meiji Seika SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 29: Global Sales for Bipolar Disorder by Region, 2014-2024
  • Figure 30: Global Sales for Bipolar Disorder by Drug Class, 2014-2024
  • Figure 31: Sales for Bipolar Disorder in the US by Drug Class, 2014-2024
  • Figure 32: Sales for Bipolar Disorder in the 5EU by Drug Class, 2014-2024
  • Figure 33: Sales for Bipolar Disorder in Japan by Drug Class, 2014-2024
  • Figure 34: Sales for Bipolar Disorder in Canada by Drug Class, 2014-2024
Back to Top